Archive for 2008
May 5, 2008
New Player in Colon Cancer Genesis Identified
In a study published today in Cancer Cell, a group led by LICR Affiliate Dr. Kari Alitalo (Helsinki, Finland), identified the PROX1 protein as a key driver of colon cancer tumorigenesis.
April 28, 2008
Richard Kolodner Elected to American Academy of Arts and Sciences
Dr. Richard D. Kolodner, LICR’s Executive Director of Laboratory Science and Technology and a Member of the LICR San Diego Branch, was today elected a Fellow of the prestigious American Academy of Arts and Sciences.
April 15, 2008
LICR’s First Spin-off Company Acquired by Roche
PIramed, the first spin-off company from the Ludwig Institute for Cancer Research, was today acquired by the pharmaceutical company, Roche. PIramed was formed in 2003 to exploit inhibitors targeting the PI-3 kinase family of enzymes. The inhibitors - and most of the PI-3 kinases - were first characterized by a group led by the Founding Director of the LICR London Branch, Michael D. Waterfield, F.R.S.
February 12, 2008
Ludwig Institute for Cancer Research receives Largest 2009 Grant from NHMRC
The National Health & Medical Research Council (NHMRC) of Australia has awarded its largest grant for 2009 to the Ludwig Institute for Cancer Research (LICR) in Melbourne.
February 4, 2008
Resisting Lung Cancer Recurrence
What if we could prevent cancer recurrence for years after surgery by giving simple recall injections every two or three years? This concept may no longer be a fantasy. In a clinical study published online this week by the Proceedings of the National Academy of Sciences USA, a team headed by the international Ludwig Institute for Cancer Research (LICR) has shown that a vaccine against a protein found in cancer cells produces an immune response that can be boosted and strengthened with additional vaccine shots.